Blanche S, et al. - Researchers examined the growth of HIV-exposed uninfected infants enrolled in ANRS 12174 (a multicenter, randomized, controlled trial of infant prophylaxis to prevent HIV type 1 transmission by breastfeeding) in correlation to taking lopinavir–ritonavir vs lamivudine. Infants given lopinavir–ritonavir showed less weight gain than those given lamivudine. This indicates a tenacious effect that could have long-term harmful effects. They recommend considering this finding in view of recommendations for early and lifelong treatment of infants with HIV.